Comparative Pharmacology
Head-to-head clinical analysis: SULSOXIN versus SULSTER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSOXIN versus SULSTER.
SULSOXIN vs SULSTER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Sulster is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thus bacterial DNA replication.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
2.5 mg orally twice daily.
None Documented
None Documented
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Terminal half-life 3.5-4.5 hours in normal renal function; prolonged to 10-15 hours with creatinine clearance <30 mL/min.
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Primarily renal (60-70% unchanged), with 20-30% as glucuronide conjugate; biliary/fecal <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic